Anzeige
Erschienen in:
27.11.2023 | Original Article
Computed tomography radiomic feature analysis of thymic epithelial tumors: Differentiation of thymic epithelial tumors from thymic cysts and prediction of histological subtypes
Erschienen in: Japanese Journal of Radiology | Ausgabe 4/2024
Einloggen, um Zugang zu erhaltenAbstract
Purpose
To investigate the value of computed tomography (CT) radiomic feature analysis for the differential diagnosis between thymic epithelial tumors (TETs) and thymic cysts, and prediction of histological subtypes of TETs.
Materials and Methods
Twenty-four patients with TETs (13 low-risk and 9 high-risk thymomas, and 2 thymic carcinomas) and 12 with thymic cysts were included in this study. For each lesion, the radiomic features of a volume of interest covering the lesion were extracted from non-contrast enhanced CT images. The Least Absolute Shrinkage and Selection Operator (Lasso) method was used for the feature selection. Predictive models for differentiating TETs from thymic cysts (model A), and high risk thymomas + thymic carcinomas from low risk thymomas (model B) were created from the selected features. The receiver operating characteristic curve was used to evaluate the effectiveness of radiomic feature analysis for differentiating among these tumors.
Results
In model A, the selected 5 radiomic features for the model A were NGLDM_Contrast, GLCM_Correlation, GLZLM_SZLGE, DISCRETIZED_HISTO_Entropy_log2, and DISCRETIZED_HUmin. In model B, sphericity was the only selected feature. The area under the curve, sensitivity, and specificity of radiomic feature analysis were 1 (95% confidence interval [CI]: 1–1), 100%, and 100%, respectively, for differentiating TETs from thymic cysts (model A), and 0.76 (95%CI: 0.53–0.99), 64%, and 100% respectively, for differentiating high-risk thymomas + thymic carcinomas from low-risk thymomas (model B).
Conclusion
CT radiomic analysis could be utilized as a non-invasive imaging technique for differentiating TETs from thymic cysts, and high-risk thymomas + thymic carcinomas from low-risk thymomas.